Last reviewed · How we verify
Livercellgram
Livercellgram is a Biologic drug developed by Pharmicell Co., Ltd.. It is currently in Phase 2 development. Also known as: Autologous bone marrow-derived mesenchymal stem cell.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Livercellgram |
|---|---|
| Also known as | Autologous bone marrow-derived mesenchymal stem cell |
| Sponsor | Pharmicell Co., Ltd. |
| Modality | Biologic |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Follow-up Study of Livercellgram in Alcoholic LC Patients Who Completed Livercellgram Phase 2 Study
- REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Livercellgram CI brief — competitive landscape report
- Livercellgram updates RSS · CI watch RSS
- Pharmicell Co., Ltd. portfolio CI
Frequently asked questions about Livercellgram
What is Livercellgram?
Who makes Livercellgram?
Is Livercellgram also known as anything else?
What development phase is Livercellgram in?
Related
- Manufacturer: Pharmicell Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Also known as: Autologous bone marrow-derived mesenchymal stem cell
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing